Table 2.
Relationship between lysyl oxidase and clinicopathological factors in patients with gastric cancer
| Characteristics | Sample size, n |
LOX |
P | |
| Low expression (%) | High expression (%) | |||
| Gender | 90 (64.3) | 50 (35.7) | ||
| Male | 112 | 73 (65.2) | 39 (34.8) | 0.659 |
| Female | 28 | 17 (60.7) | 11 (39.3) | |
| Age | ||||
| < 60 yr | 67 | 44 (65.7) | 23 (34.3) | 0.743 |
| ≥ 60 yr | 73 | 46 (63.0) | 27 (37.0) | |
| Tumor location | ||||
| Upper part | 57 | 37 (64.9) | 20 (35.1) | 0.978 |
| Middle part | 34 | 21 (61.8) | 13 (38.2) | |
| Lower part | 44 | 29 (65.9) | 15 (34.1) | |
| Total stomach | 5 | 3 (60.0) | 2 (40.0) | |
| Tumor size | ||||
| < 5 cm | 57 | 39 (68.4) | 18 (31.6) | 0.397 |
| ≥ 5 cm | 83 | 51 (61.4) | 32 (38.6) | |
| Depth of invasion | ||||
| T1 | 5 | 5 (100.0) | 0 (0.0) | 0.005 |
| T2 | 13 | 12 (92.3) | 1 (7.7) | |
| T3 | 85 | 56 (65.9) | 29 (34.1) | |
| T4 | 37 | 17 (45.9) | 20 (54.1) | |
| Lymphatic metastasis | ||||
| 0 | 34 | 33 (97.1) | 1 (2.9) | 0.000 |
| 1-2 | 32 | 24 (75.0) | 8 (25.0) | |
| 3-6 | 31 | 21 (67.7) | 10 (32.3) | |
| 7-15 | 37 | 12 (32.4) | 25 (67.6) | |
| ≥ 16 | 6 | 0 (0.0) | 6 (100.0) | |
| Borrmann classification | ||||
| Type I | 16 | 12 (75.0) | 4 (25.0) | 0.340 |
| Type II or III | 110 | 67 (60.9) | 43 (39.1) | |
| Type IV | 11 | 8 (72.7) | 3 (27.3) | |
| Type V | 3 | 3 (100.0) | 0 (0.0) | |
| WHO histological classification | ||||
| Adenocarcinoma | 77 | 48 (62.3) | 29 (37.7) | 0.862 |
| Signet-ring cell carcinoma | 17 | 13 (76.5) | 4 (23.5) | |
| Mucinous adenocarcinoma | 8 | 5 (62.5) | 3 (37.5) | |
| Mixed carcinoma | 32 | 20 (62.5) | 12 (37.5) | |
| Neuroendocrine carcinoma | 6 | 4 (66.7) | 2 (33.3) | |
| Lauren parting | ||||
| Intestinal type | 65 | 42 (64.6) | 23 (35.4) | 0.909 |
| Diffuse type | 68 | 43 (63.2) | 25 (36.8) | |
| Mixed type | 7 | 5 (71.4) | 2 (28.6) | |
| Differentiation grade | ||||
| Low and middle | 107 | 68 (63.6) | 39 (36.4) | 0.744 |
| High | 33 | 22 (66.7) | 11 (33.3) | |
| Cancer embolus | ||||
| Yes | 51 | 29 (56.9) | 22 (43.1) | 0.165 |
| No | 89 | 61 (68.5) | 28 (31.5) | |
| Affect neural | ||||
| Yes | 50 | 29 (58.0) | 21 (42.0) | 0.247 |
| No | 90 | 61 (67.8) | 29 (32.2) | |
| TNM staging | ||||
| I | 10 | 10 (100.0) | 0 (0.0) | 0.000 |
| II | 49 | 44 (89.8) | 5 (10.2) | |
| III | 81 | 36 (44.4) | 45 (55.6) | |
LOX: Lysyl oxidase; WHO: Word Health Organization; TNM: Tumor-node-metastasis.